Sanofi: alliance with Teva in two bowel diseases
(CercleFinance.com) - Sanofi announces a collaboration with Teva to co-develop and co-market TEV'574, which is currently in Phase IIb clinical trials, for the treatment of ulcerative colitis and Crohn's disease, two inflammatory bowel diseases.
Under the new agreement, Teva will receive an upfront payment of E469m and up to E940m in milestone payments, depending on the achievement of development and commercialisation targets.
The companies will share worldwide development costs, as well as net profits and losses in key markets. In other markets, royalty agreements will be implemented.
Sanofi will lead the development activities applicable to the Phase III program, and the companies will share commercialisation internationally. The first results of the program should be available in 2024.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
Under the new agreement, Teva will receive an upfront payment of E469m and up to E940m in milestone payments, depending on the achievement of development and commercialisation targets.
The companies will share worldwide development costs, as well as net profits and losses in key markets. In other markets, royalty agreements will be implemented.
Sanofi will lead the development activities applicable to the Phase III program, and the companies will share commercialisation internationally. The first results of the program should be available in 2024.
Copyright (c) 2023 CercleFinance.com. All rights reserved.